 |
|
Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents
Nirat Beohar, MD;
Charles J. Davidson, MD;
Kevin E. Kip, PhD;
Lynne Goodreau, MS;
Helen Aslanidou Vlachos, MSc;
Sheridan N. Meyers, MD;
Keith H. Benzuly, MD;
James D. Flaherty, MD;
Mark J. Ricciardi, MD;
Charles L. Bennett, MD, PhD, MPP;
David O. Williams, MD
JAMA. 2007;297(18):1992-2000.
Context Limited data exist regarding use of drug-eluting stents outside of approved indications in real-world settings.
Objectives To determine the frequency, safety, and effectiveness of drug-eluting stents for off-label (restenosis, bypass graft lesion, long lesions, vessel size outside of information for use recommendation) and untested (left main, ostial, bifurcation, or total occlusion lesions) indications in percutaneous coronary intervention (PCI).
Design, Setting, and Patients Observational, prospective, multicenter registry to evaluate in-hospital, 30-day, and 1-year outcomes among patients undergoing PCI between January and June 2005 in 140 US academic and community medical centers. Of 7752 PCI-treated patients, 6993 (90%) received drug-eluting stents; of these, 5851 (84%) received no other devices. Standard, off-label, and untested use was determined in 5541 (95%) of these 5851 patients, constituting the study cohort.
Main Outcome Measures Frequency of off-label and untested use, 1-year repeat target vessel revascularization, and composite of death, myocardial infarction (MI), or stent thrombosis at in-hospital follow-up and during 1 year of follow-up.
Results Of 5541 patients receiving drug-eluting stents, 2588 (47%) received stents for off-label or untested indications. Adjusted in-hospital risk of death, MI, or stent thrombosis was not statistically different with off-label or untested vs standard use. At 30 days, the risk of this composite end point was significantly higher with off-label use (adjusted hazard ratio [HR], 2.08; 95% confidence interval [CI], 1.24-3.48; P = .005) but not untested use (adjusted HR, 1.45; 95% CI, 0.79-2.67; P = .23). Excluding early events, this end point was not different at 1 year with off-label use (adjusted HR, 1.10; 95% CI, 0.79-1.54; P = .57) or untested use (adjusted HR, 0.91; 95% CI, 0.60-1.38; P = .66). At 1 year, compared with standard use, significantly higher rates of target vessel revascularization were associated with off-label use (adjusted HR, 1.49; 95% CI, 1.13-1.98; P = .005) and untested use (adjusted HR, 1.49; 95% CI, 1.10-2.02; P = .01), although absolute rates were low (standard, 4.4% [n = 113]; off-label, 7.6% [n = 95]; untested, 6.7% [n = 72]).
Conclusions In contemporary US practice, off-label and untested use of drug-eluting stents is common. Compared with standard use, relative early safety is lower with off-label use, and the long-term effectiveness is lower with both off-label and untested use. However, the absolute event rates remain low.
Author Affiliations: Northwestern University Feinberg School of Medicine, Chicago, Ill (Drs Beohar, Davidson, Meyers, Benzuly, Flaherty, Ricciardi, and Bennett and Ms Goodreau); University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pa (Dr Kip and Ms Vlachos); and Brown University School of Medicine, Providence, RI (Dr Williams).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Off-Label Use of Drug-Eluting Stents
Ravi K. Bobba, Madhavi Bollu, and Edward L. Arsura
JAMA. 2007;298(8):859.
EXTRACT
| FULL TEXT
Outcomes of Medicare Beneficiaries With Ventricular Assist Devices—Reply
Adrian F. Hernandez, Bradley G. Hammill, and Lesley H. Curtis
JAMA. 2009;301(16):1658.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Clinical Outcomes and Stent Thrombosis Following Off-Label Use of Drug-Eluting Stents
Htut K. Win, Angel E. Caldera, Kelly Maresh, John Lopez, Charanjit S. Rihal, Manish A. Parikh, Juan F. Granada, Sachin Marulkar, Deborah Nassif, David J. Cohen, Neal S. Kleiman, and for the EVENT Registry Investigators
JAMA. 2007;297(18):2001-2009.
ABSTRACT
| FULL TEXT
The Enigma of Drug-Eluting Stents: Hope, Hype, Humility, and Advancing Patient Care
Robert A. Harrington and E. Magnus Ohman
JAMA. 2007;297(18):2028-2030.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period
Schulz et al.
Eur Heart J 2009;30:2714-2721.
ABSTRACT
| FULL TEXT
Temporal Changes in the Use of Drug-Eluting Stents for Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention From 2006 to 2008: Results From the Can Rapid risk stratification of Unstable angina patients Supress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) and Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (ACTION-GWTG) Registries
Roe et al.
Circ Cardiovasc Qual Outcomes 2009;2:414-420.
ABSTRACT
| FULL TEXT
Off-Label Use and the Spectre of Drug-Eluting Stent Thrombosis
Cook and Wenaweser
Circ Cardiovasc Interv 2009;2:273-276.
FULL TEXT
Catheter-Based Delivery of Fluid Paclitaxel for Prevention of Restenosis in Native Coronary Artery Lesions After Stent Implantation
Herdeg et al.
Circ Cardiovasc Interv 2009;2:294-301.
ABSTRACT
| FULL TEXT
Drug-Eluting Stent Thrombosis in Routine Clinical Practice: Two-Year Outcomes and Predictors From the TAXUS ARRIVE Registries
Lasala et al.
Circ Cardiovasc Interv 2009;2:285-293.
ABSTRACT
| FULL TEXT
Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications.
Ko et al.
J Am Coll Cardiol 2009;53:1773-1782.
ABSTRACT
| FULL TEXT
Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction
Stone et al.
NEJM 2009;360:1946-1959.
ABSTRACT
| FULL TEXT
Outcomes of Medicare Beneficiaries With Ventricular Assist Devices--Reply
Hernandez et al.
JAMA 2009;301:1658-1658.
FULL TEXT
Outcome of Drug-Eluting Versus Bare-Metal Stenting Used According to On- and Off-Label Criteria
Carlsson et al.
J Am Coll Cardiol 2009;53:1389-1398.
ABSTRACT
| FULL TEXT
Impact of Drug-Eluting Versus Bare-Metal Stents on Mortality in Patients With Anemia
Shishehbor et al.
J Am Coll Cardiol Intv 2009;2:329-336.
ABSTRACT
| FULL TEXT
Baseline Fractional Flow Reserve and Stent Diameter Predict Optimal Post-Stent Fractional Flow Reserve and Major Adverse Cardiac Events After Bare-Metal Stent Deployment
Samady et al.
J Am Coll Cardiol Intv 2009;2:357-363.
ABSTRACT
| FULL TEXT
3-Year Comparison of Drug-Eluting Versus Bare-Metal Stents
Applegate et al.
J Am Coll Cardiol Intv 2009;2:231-239.
ABSTRACT
| FULL TEXT
Drug-eluting stent thrombosis
Stahli et al.
Ther Adv Cardiovasc Dis 2009;3:45-52.
ABSTRACT
Twenty-Year Evolution of Percutaneous Coronary Intervention and Its Impact on Clinical Outcomes: A Report From the National Heart, Lung, and Blood Institute-Sponsored, Multicenter 1985-1986 PTCA and 1997-2006 Dynamic Registries
Venkitachalam et al.
Circ Cardiovasc Interv 2009;2:6-13.
ABSTRACT
| FULL TEXT
Current Status of Percutaneous Coronary Intervention With Drug-Eluting Stents in Asia
Park and Kim
Circulation 2008;118:2730-2737.
FULL TEXT
Long-Term Clinical Benefit of Sirolimus-Eluting Stents in Patients With In-Stent Restenosis: Results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) Study
Alfonso et al.
J Am Coll Cardiol 2008;52:1621-1627.
ABSTRACT
| FULL TEXT
Long-Term Clinical Outcomes After Drug-Eluting and Bare-Metal Stenting in Massachusetts
Mauri et al.
Circulation 2008;118:1817-1827.
ABSTRACT
| FULL TEXT
Preliminary Results of the Hydroxyapatite Nonpolymer-Based Sirolimus-Eluting Stent for the Treatment of Single De Novo Coronary Lesions: A First-in-Human Analysis of a Third-Generation Drug-Eluting Stent System
Costa et al.
J Am Coll Cardiol Intv 2008;1:545-551.
ABSTRACT
| FULL TEXT
Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications: A Propensity Score-Matched Outcome Study
Austin et al.
Circ Cardiovasc Interv 2008;1:45-52.
ABSTRACT
| FULL TEXT
Outcomes and Complications With Off-Label Use of Drug-Eluting Stents: Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group
Brodie et al.
J Am Coll Cardiol Intv 2008;1:405-414.
ABSTRACT
| FULL TEXT
Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention
Newsome et al.
Anesth. Analg. 2008;107:552-569.
ABSTRACT
| FULL TEXT
Outcomes Following Coronary Stenting in the Era of Bare-Metal vs the Era of Drug-Eluting Stents
Malenka et al.
JAMA 2008;299:2868-2876.
ABSTRACT
| FULL TEXT
The year in interventional cardiology.
Dixon et al.
J Am Coll Cardiol 2008;51:2355-2369.
FULL TEXT
The evolution of thienopyridine therapy clopidogrel duration, diabetes, and drug-eluting stents.
Choi et al.
J Am Coll Cardiol 2008;51:2228-2229.
FULL TEXT
Bare-Metal versus Drug-Eluting Coronary Stents
Austin et al.
NEJM 2008;358:2516-2518.
FULL TEXT
Hospital and operator variations in drug-eluting stent use: a multi-level analysis of 5967 consecutive patients in Scotland
Austin et al.
J Public Health (Oxf) 2008;30:186-193.
ABSTRACT
| FULL TEXT
Drug-Eluting Stents: Life Insurance With a Better Death Benefit
Anderson
J Am Coll Cardiol 2008;51:2025-2027.
FULL TEXT
Studies of Drug-Eluting Stents: To Each His Own?
Mauri and Normand
Circulation 2008;117:2047-2050.
FULL TEXT
Drug-Eluting Versus Bare-Metal Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction
Hannan et al.
J Am Coll Cardiol Intv 2008;1:129-135.
ABSTRACT
| FULL TEXT
The left main facts: faced, spun, but alas too few.
Brinker
J Am Coll Cardiol 2008;51:893-898.
ABSTRACT
| FULL TEXT
Off-label use of drug-eluting stents putting it in perspective.
Grines
J Am Coll Cardiol 2008;51:615-617.
FULL TEXT
Drug-eluting stents: do the risks really outweigh the benefits?
Austin et al.
Heart 2008;94:127-128.
FULL TEXT
A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications
Marroquin et al.
NEJM 2008;358:342-352.
ABSTRACT
| FULL TEXT
Drug-Eluting Stents -- Pushing the Envelope beyond the Labels?
Carrozza
NEJM 2008;358:405-407.
FULL TEXT
Peeling-Off Labels: Mounting Evidence for Benefit of Drug-Eluting Stents With Off-Label Use
Buttner and Neumann
J Am Coll Cardiol 2007;50:2037-2038.
FULL TEXT
Et Tu, Bare Metal Stent?
Williams and Abbott
Circulation 2007;116:2363-2365.
FULL TEXT
Invited commentary
Ott
Ann. Thorac. Surg. 2007;84:1727-1728.
FULL TEXT
Coronary Stents and Noncardiac Surgery
Riddell et al.
Circulation 2007;116:e378-e382.
FULL TEXT
JournalScan
Lindsay
Heart 2007;93:1159-1160.
FULL TEXT
Off-Label Use of Drug-Eluting Stents
Bobba et al.
JAMA 2007;298:859-859.
FULL TEXT
Off-Label Drug-Eluting Stent Use Increases Risk for Adverse Events
Journal Watch Cardiology 2007;2007:1-1.
FULL TEXT
Off-Label Use of Drug-Eluting Coronary Artery Stents
JWatch General 2007;2007:3-3.
FULL TEXT
The Enigma of Drug-Eluting Stents: Hope, Hype, Humility, and Advancing Patient Care
Harrington and Ohman
JAMA 2007;297:2028-2030.
FULL TEXT
|
